PBIO Stock Overview
Develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pressure BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.004 |
| 52 Week High | US$0.50 |
| 52 Week Low | US$0.0005 |
| Beta | -0.057 |
| 1 Month Change | 233.33% |
| 3 Month Change | -71.43% |
| 1 Year Change | -99.20% |
| 3 Year Change | -99.82% |
| 5 Year Change | -99.55% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| PBIO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 14.3% | 4.1% | 0.7% |
| 1Y | -99.2% | -0.9% | 23.0% |
Return vs Industry: PBIO underperformed the US Life Sciences industry which returned -0.9% over the past year.
Return vs Market: PBIO underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| PBIO volatility | |
|---|---|
| PBIO Average Weekly Movement | 173.0% |
| Life Sciences Industry Average Movement | 9.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PBIO's weekly volatility has decreased from 240% to 173% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 16 | Richard Schumacher | www.pressurebiosciences.com |
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company’s products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formulations; BaroFold Technology platform, that is used to improve the quality and lower the production costs of protein biotherapeutics; and Pressure Cycling Technology platform which uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions in sample preparation. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB440, Barocycler HUB880, and the Shredder SG3; Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, and PCT-Micro Pestle; UltraShear Mini, UltraShear K45, and UltraShear Max; and application specific kits, as well as consumable products.
Pressure BioSciences, Inc. Fundamentals Summary
| PBIO fundamental statistics | |
|---|---|
| Market cap | US$266.29k |
| Earnings (TTM) | -US$36.62m |
| Revenue (TTM) | US$1.59m |
0.1x
P/S Ratio0.0x
P/E RatioIs PBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBIO income statement (TTM) | |
|---|---|
| Revenue | US$1.59m |
| Cost of Revenue | US$1.05m |
| Gross Profit | US$533.54k |
| Other Expenses | US$37.15m |
| Earnings | -US$36.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 33.63% |
| Net Profit Margin | -2,308.30% |
| Debt/Equity Ratio | -69.5% |
How did PBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 18:04 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pressure BioSciences, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Resnik | Merriman Capital, Inc |
| null null | SeeThruEquity, LLC |
| Juan Noble | Taglich Brothers, Inc. |